目的 探讨养血清脑丸联合苯甲酸利扎曲普坦片治疗偏头痛的临床疗效。方法 选取2019年5月-2020年5月在漯河市中心医院就诊的118例偏头痛患者，按照随机数字法分为对照组（59例）和治疗组（59例）。对照组口服苯甲酸利扎曲普坦片，10 mg/次，3次/d。治疗组在对照组基础上口服养血清脑丸，2.5 g/次，3次/d。两组患者连续治疗1个月。观察用药后的治疗效果、临床症状、血流速度指标、血清中相关因子和不良反应情况。结果 治疗组治疗后的总有效率为93.22%，明显高于对照组的71.19%（P<0.05）。两组患者经过药物治疗后，头痛持续时间评分、头痛程度评分和头痛指数均较治疗前明显改善（P<0.05），且治疗组较对照组症状明显减轻（P<0.05）。两组患者经过药物治疗后，大脑前动脉、中动脉、椎动脉、后动脉和基底动脉的血流速度较治疗前明显改善（P<0.05），且治疗组的血流速度明显低于对照组（P<0.05）。两组患者经过药物治疗后，氧化型低密度脂蛋白（ox-LDL）、内皮素-1（ET-1）、环氧合酶2（COX-2）和5-羟色胺（5-HT）较治疗后明显降低（P<0.05），对氧磷酶-1（PON-1）明显升高（P<0.05），而治疗组这些指标较对照组明显改善（P<0.05）。结论 养血清脑丸联合苯甲酸利扎曲普坦片治疗偏头痛总有效率高，能够缓解临床症状，改善血流速度指标，调节ox-LDL、ET-1、COX-2、5-HT和PON-1水平，具有一定的临床推广应用价值。

Objective To investigate the therapeutic effect of Yangxue Qingnao Pills combined with rizatriptan monobenzoate in treatment of migraine. Methods Patients (118 case) with migraine in Luohe Central Hospital from May 2019 to May 2020 were randomly divided into control (59 cases) and treatment (59 cases) groups. Patients in the control group were po administered with Rizatriptan Monobenzoate Tablets, 10 mg/time, three times daily. Patients in the treatment group were po administered with Yangxue Qingnao Pills on the basis of the control group, 2.5 g/time, three times daily. Patients in two groups were treated for 1 month. The therapeutic effect, the improvement of clinical symptoms, blood flow velocity index, serum related factors were observed. Results The clincial effective rate of the treatment group after treatment was 93.22%, which was significantly higher than 71.19% of the control group (P<0.05). After treatment, the headache duration, headache degree and headache index in the two groups were significantly improved as compared with those before treatment (P<0.05), and the symptoms in the treatment group were significantly relieved than those in the control group (P<0.05). After treatment, the blood flow velocities of anterior cerebral artery, middle artery, vertebral artery, posterior artery and basilar artery in the two groups were significantly improved as compared with those before treatment (P<0.05), and the blood flow velocity in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, ox-LDL, ET-1, COX-2 and 5-HT in the two groups were significantly decreased (P<0.05), but PON-1 was significantly increased (P<0.05), while these indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Yangxue Qingnao Pills combined with rizatriptan monobenzoate in treatment of migraine has a higher overall efficiency, which can relieve clinical symptoms, improve blood flow velocity indexes, and ox-LDL, ET-1, COX-2, 5-HT and PON-1 levels, which has a certain clinical application value.

R971